Gyre Therapeutics (NASDAQ:GYRE) Trading Down 7.5%

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares fell 7.5% during mid-day trading on Friday . The company traded as low as $14.00 and last traded at $14.14. 23,604 shares changed hands during trading, a decline of 70% from the average session volume of 78,337 shares. The stock had previously closed at $15.29.

Gyre Therapeutics Stock Down 6.5 %

The stock’s fifty day moving average price is $16.39 and its 200 day moving average price is $17.75.

Insiders Place Their Bets

In other news, Director Nassim Usman sold 20,000 shares of Gyre Therapeutics stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total transaction of $282,600.00. Following the completion of the sale, the director now owns 1,636 shares of the company’s stock, valued at $23,116.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.92% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.